Headquartered in South San Francisco, CA·Fiscal year ends December·NASDAQ: RIGL·rigel.com
About Rigel Pharmaceuticals
Rigel Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops and markets therapies for hematologic disorders and cancer. It sells four products in the U.S.:
- **TAVALISSE (fostamatinib):** for chronic immune thrombocytopenia (ITP).
- **REZLIDHIA (olutasidenib):** for relapsed or refractory IDH1-mutated acute myeloid leukemia.
- **GAVRETO (pralsetinib):** for RET fusion-positive non-small cell lung cancer and thyroid cancer.
- **VEPPANU (vepdegestrant):** an oral PROTAC degrader for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, launched in August 2026 after a transfer from Arvinas and Pfizer.
Rigel also earns contract revenues, including royalties, milestones and drug-supply sales, from partners Grifols, Kissei, Medison and Knight Therapeutics, which commercialize fostamatinib outside the U.S. Its lead pipeline asset is R289, a dual IRAK1/4 inhibitor in Phase 1b development for relapsed or refractory lower-risk myelodysplastic syndrome. Updated
Thursday's top analyst upgrades and downgrades included Affirm, Bloom Energy, Carlyle, Dutch Bros, Fiserv, Hanesbrands, LyondellBasell Industries, Microsoft, Rigel Pharmaceutical, Target, Tesla and Twilio.
Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.